Arix Bioscience PLC has announced that its portfolio company, Aura Biosciences, has successfully closed a public offering of common stock, raising approximately $99 million. Aura received net proceeds of around $92.6 million from the offering, which it plans to use for the clinical development of belzupacap sarotalocan, a treatment for choroidal melanoma and choroidal metastasis, as well as for platform development and general corporate purposes. Aura believes that the funds raised, combined with its existing cash and marketable securities, will be sufficient to cover its operating expenses and capital expenditure requirements until the second half of 2026. Arix holds 1,508,483 shares in Aura, and the value of these shares will be determined by the market price of Aura's shares.